Seattle Treatment Education Project

Gilead's Truvada Is Approved by the FDA

August 30, 2004

The Food and Drug Administration approved Gilead's Truvada, a one-tablet, once-a-day dosed co-formulation of Viread and Emtriva. This medication combines 200 mg of emtricitabine and 300 mg of tenofovir fumarate.

This once-a-day new combination may make it easier for doctors when prescribing new regimens. Truvada must be taken in combination with other anti-HIV medications to achieve maximum viral suppression.

The company is planning to sell Truvada to the developing world at a not-profit price through Gilead's Access Program. The developing world counts for more than 70% of all infections. For more information on Truvada, go to Gilead.com, talk to your doctor or call the STEP Program at 1-888-399-7837.

Back to the STEP Ezine Volume 1, Issue 60 contents page.

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.

My Health Tracker

Widgets and RSS Feeds

U.S. ASO Finder

The First Man to Be Cured of AIDS: An Update on the Amazing Story -- This Month in HIV

OIs and Co-Infections and STIs -- Oh, My!

HIV Antiretrovirals in Development: An Update From ICAAC 2009

Back From the Brink: A Blog Entry by Thomas DeLorenzo

World AIDS Day 2009: Home

More >>

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.